BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 11006136)

  • 1. A review of angiogenesis and antiangiogenic therapy with thalidomide in multiple myeloma.
    Rajkumar SV; Witzig TE
    Cancer Treat Rev; 2000 Oct; 26(5):351-62. PubMed ID: 11006136
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thalidomide in the treatment of multiple myeloma.
    Rajkumar SV
    Expert Rev Anticancer Ther; 2001 Jun; 1(1):20-8. PubMed ID: 12113124
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current status of thalidomide in the treatment of cancer.
    Rajkumar SV
    Oncology (Williston Park); 2001 Jul; 15(7):867-74; discussion 877-9. PubMed ID: 11499688
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thalidomide in multiple myeloma.
    Rajkumar SV
    Oncology (Williston Park); 2000 Dec; 14(12 Suppl 13):11-6. PubMed ID: 11204667
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High plasma basic fibroblast growth factor concentration is associated with response to thalidomide in progressive multiple myeloma.
    Neben K; Moehler T; Egerer G; Kraemer A; Hillengass J; Benner A; Ho AD; Goldschmidt H
    Clin Cancer Res; 2001 Sep; 7(9):2675-81. PubMed ID: 11555579
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antitumor activity of thalidomide in refractory multiple myeloma.
    Singhal S; Mehta J; Desikan R; Ayers D; Roberson P; Eddlemon P; Munshi N; Anaissie E; Wilson C; Dhodapkar M; Zeddis J; Barlogie B
    N Engl J Med; 1999 Nov; 341(21):1565-71. PubMed ID: 10564685
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Angiogenesis in multiple myeloma.
    Rajkumar SV; Kyle RA
    Semin Oncol; 2001 Dec; 28(6):560-4. PubMed ID: 11740809
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Thalidomide for the treatment of refractory multiple myeloma].
    Kakimoto T; Hattori Y; Okamoto S
    Rinsho Ketsueki; 2002 May; 43(5):345-8. PubMed ID: 12096483
    [No Abstract]   [Full Text] [Related]  

  • 9. [New observations support the significance of angiogenesis in myeloma].
    Lundberg LG; Lerner R; Palmblad J
    Lakartidningen; 2001 Nov; 98(45):4985-90. PubMed ID: 11816901
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correspondence re: K. Neben et al., high plasma basic fibroblast growth factor concentration is associated with response to thalidomide in progressive multiple myeloma. Clin. Cancer Res., 7: 2675-2681, 2001.
    Go RS; Horstman AL
    Clin Cancer Res; 2002 Aug; 8(8):2750; author reply 2751. PubMed ID: 12171909
    [No Abstract]   [Full Text] [Related]  

  • 11. Salvage therapy with thalidomide in patients with advanced relapsed/refractory multiple myeloma.
    Tosi P; Zamagni E; Cellini C; Ronconi S; Patriarca F; Ballerini F; Musto P; Di Raimondo F; Ledda A; Lauria F; Masini L; Gobbi M; Vacca A; Ria R; Cangini D; Tura S; Baccarani M; Cavo M
    Haematologica; 2002 Apr; 87(4):408-14. PubMed ID: 11940485
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Bone marrow angiogenesis in multiple myeloma: new insights into the pathogenesis, and development of a new therapeutic approach].
    Hattori Y; Kakimoto T
    Rinsho Ketsueki; 2000 May; 41(5):426-9. PubMed ID: 10879105
    [No Abstract]   [Full Text] [Related]  

  • 13. Thalidomide: when everything old is new again.
    Nirenberg A
    Clin J Oncol Nurs; 2001; 5(1):15-8. PubMed ID: 11899395
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Thalidomide. Clinical trials in cancer].
    Politi PM
    Medicina (B Aires); 2000; 60 Suppl 2():61-5. PubMed ID: 11188934
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Role of thalidomide in the treatment of multiple myeloma].
    Mikala G; Jákó J; Vályi-Nagy I
    Orv Hetil; 2001 Aug; 142(33):1789-98. PubMed ID: 11573449
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel biologically based therapies for myeloma.
    Anderson KC
    Cancer J; 2001; 7 Suppl 1():S19-23. PubMed ID: 11504280
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diabetic foot disease in a patient with multiple myeloma receiving thalidomide.
    Pitini V; Arrigo C; Aloi G; Azzarello D; La Gattuta G
    Haematologica; 2002 Feb; 87(2):ELT07. PubMed ID: 11836184
    [No Abstract]   [Full Text] [Related]  

  • 18. A pilot study of thalidomide in patients with progressive metastatic renal cell carcinoma.
    Daliani DD; Papandreou CN; Thall PF; Wang X; Perez C; Oliva R; Pagliaro L; Amato R
    Cancer; 2002 Aug; 95(4):758-65. PubMed ID: 12209719
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thalidomide--a revival story.
    Raje N; Anderson K
    N Engl J Med; 1999 Nov; 341(21):1606-9. PubMed ID: 10564693
    [No Abstract]   [Full Text] [Related]  

  • 20. Thalidomide in the treatment of relapsed multiple myeloma.
    Rajkumar SV; Fonseca R; Dispenzieri A; Lacy MQ; Lust JA; Witzig TE; Kyle RA; Gertz MA; Greipp PR
    Mayo Clin Proc; 2000 Sep; 75(9):897-901. PubMed ID: 10994824
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.